Peter F. Lenehan

1.1k total citations
18 papers, 831 citations indexed

About

Peter F. Lenehan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Peter F. Lenehan has authored 18 papers receiving a total of 831 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Peter F. Lenehan's work include HER2/EGFR in Cancer Research (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Peter F. Lenehan is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Peter F. Lenehan collaborates with scholars based in United States, Canada and United Kingdom. Peter F. Lenehan's co-authors include Irene Eiseman, David W. Fry, William J. Slichenmyer, Eric J. Small, Mario A. Eisenberger, Stephen C. Olson, Arpit A. Almal, Liang Chen, Leonard Reyno and Ronald B. Natale and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Peter F. Lenehan

18 papers receiving 797 citations

Peers

Peter F. Lenehan

ONCOL

PRM

MB

RNMI

CR

Toshio Fujino Japan

Bianco Ar Italy

A. Craig Lockhart United States

Young‐Kwang Yoon South Korea

Christopher Ruel United States

Andrea Milani Italy

Regula Deurloo Switzerland

Parvin F. Peddi United States

Federica Martorana Italy

Caterina Fontanella Italy

Toshio Fujino Japan

Peter F. Lenehan

420 ×0.9

ONCOL

563 ×1.4

PRM

402 ×1.5

MB

72 ×0.5

RNMI

142 ×1.1

CR

Citations per year, relative to Peter F. Lenehan Peter F. Lenehan (= 1×) peers Toshio Fujino

Countries citing papers authored by Peter F. Lenehan

Since Specialization

Citations

This map shows the geographic impact of Peter F. Lenehan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter F. Lenehan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter F. Lenehan more than expected).

Fields of papers citing papers by Peter F. Lenehan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter F. Lenehan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter F. Lenehan. The network helps show where Peter F. Lenehan may publish in the future.

Co-authorship network of co-authors of Peter F. Lenehan

This figure shows the co-authorship network connecting the top 25 collaborators of Peter F. Lenehan. A scholar is included among the top collaborators of Peter F. Lenehan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter F. Lenehan. Peter F. Lenehan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Bartsch, Georg, Anirban P. Mitra, Arpit A. Almal, et al.. (2015). Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder. The Journal of Urology. 195(2). 493–498. 43 indexed citations

2.

Lenehan, Peter F., Lisa A. Boardman, Douglas L. Riegert‐Johnson, et al.. (2012). Generation and external validation of a tumor‐derived 5‐gene prognostic signature for recurrence of lymph node‐negative, invasive colorectal carcinoma. Cancer. 118(21). 5234–5244. 31 indexed citations

3.

Sullivan, Peter, Peter Lewindon, Peter F. Lenehan, et al.. (2007). Intestinal mucosa remodeling by recombinant human epidermal growth factor1-48 in neonates with severe necrotizing enterocolitis. Journal of Pediatric Surgery. 42(3). 462–469. 32 indexed citations

4.

Jänne, Pasi A., Joachim von Pawel, Roger B. Cohen, et al.. (2007). Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(25). 3936–3944. 93 indexed citations

5.

Zinner, Ralph, John Nemunaitis, Irene Eiseman, et al.. (2007). Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer. Clinical Cancer Research. 13(10). 3006–3014. 20 indexed citations

6.

Chiappori, Alberto, Peter Ellis, John Hamm, et al.. (2006). A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(9). 1010–1019. 12 indexed citations

7.

Mitra, Anirban P., Arpit A. Almal, Ben George, et al.. (2006). The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer. 6(1). 159–159. 58 indexed citations

8.

Simon, George R., Christopher R. Garrett, Stephen C. Olson, et al.. (2006). Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study. Clinical Cancer Research. 12(15). 4645–4651. 22 indexed citations

9.

Almal, Arpit A., Anirban P. Mitra, Ram H. Datar, et al.. (2006). Using genetic programming to classify node positive patients in bladder cancer. 239–246. 1 indexed citations

10.

Chiappori, Alberto, Peter Ellis, John Hamm, et al.. (2006). A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(9). 1010–1019. 9 indexed citations

11.

Garland, Linda L., Manuel Hidalgo, David S. Mendelson, et al.. (2006). A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12(14). 4274–4282. 26 indexed citations

12.

Nemunaitis, John, Irene Eiseman, Casey Cunningham, et al.. (2005). Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer. Clinical Cancer Research. 11(10). 3846–3853. 71 indexed citations

13.

Campos, Susana M., Oday Hamid, Michael V. Seiden, et al.. (2005). Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer. Journal of Clinical Oncology. 23(24). 5597–5604. 89 indexed citations

14.

Calvo, Emiliano, Anthony W. Tolcher, Lisa A. Hammond, et al.. (2004). Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule. Clinical Cancer Research. 10(21). 7112–7120. 68 indexed citations

15.

Allen, Lee F., Peter F. Lenehan, Irene Eiseman, William L. Elliott, & David W. Fry. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Seminars in Oncology. 29(3 Suppl 11). 11–21. 52 indexed citations

16.

Meyer, Mark B., et al.. (2001). Phase 1 Drug Interaction Study of Suramin and Warfarin in Patients With Prostate Cancer. American Journal of Clinical Oncology. 24(2). 167–171. 1 indexed citations

17.

Small, Eric J., Alex McMillan, Liang Chen, et al.. (2001). Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival. Journal of Clinical Oncology. 19(5). 1304–1311. 66 indexed citations

18.

Small, Eric J., M. Ernest Marshall, Leonard Reyno, et al.. (2000). Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. Journal of Clinical Oncology. 18(7). 1440–1450. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact